245 related articles for article (PubMed ID: 33343577)
1. Identifying Potential Candidate Hub Genes and Functionally Enriched Pathways in the Immune Responses to Quadrivalent Inactivated Influenza Vaccines in the Elderly Through Co-Expression Network Analysis.
Yang J; Zhang J; Fan R; Zhao W; Han T; Duan K; Li X; Zeng P; Deng J; Zhang J; Yang X
Front Immunol; 2020; 11():603337. PubMed ID: 33343577
[TBL] [Abstract][Full Text] [Related]
2. Sex-specific differences of humoral immunity and transcriptome diversification in older adults vaccinated with inactivated quadrivalent influenza vaccines.
Yang J; Huang X; Zhang J; Fan R; Zhao W; Han T; Duan K; Li X; Zeng P; Deng J; Zhang J; Yang X
Aging (Albany NY); 2021 Mar; 13(7):9801-9819. PubMed ID: 33744852
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis identified genes responsible for distinct immune responses to trivalent inactivated and live attenuated influenza vaccines.
Wen F; Guo J; Huang S
J Cell Physiol; 2019 Apr; 234(4):5196-5202. PubMed ID: 30203415
[TBL] [Abstract][Full Text] [Related]
4. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
5. Seasonal Variability and Shared Molecular Signatures of Inactivated Influenza Vaccination in Young and Older Adults.
Avey S; Mohanty S; Chawla DG; Meng H; Bandaranayake T; Ueda I; Zapata HJ; Park K; Blevins TP; Tsang S; Belshe RB; Kaech SM; Shaw AC; Kleinstein SH
J Immunol; 2020 Mar; 204(6):1661-1673. PubMed ID: 32060136
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
8. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
9. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
Front Immunol; 2018; 9():2465. PubMed ID: 30405641
[No Abstract] [Full Text] [Related]
10. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
Front Immunol; 2018; 9():3103. PubMed ID: 30761157
[TBL] [Abstract][Full Text] [Related]
11. Integrative genomic analysis of the human immune response to influenza vaccination.
Franco LM; Bucasas KL; Wells JM; Niño D; Wang X; Zapata GE; Arden N; Renwick A; Yu P; Quarles JM; Bray MS; Couch RB; Belmont JW; Shaw CA
Elife; 2013 Jul; 2():e00299. PubMed ID: 23878721
[TBL] [Abstract][Full Text] [Related]
12. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
13. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
15. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
Dunkle LM; Izikson R; Patriarca PA; Goldenthal KL; Muse D; Cox MMJ
J Infect Dis; 2017 Dec; 216(10):1219-1226. PubMed ID: 28968871
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
Wang SY; Liu SZ; Chu K; Zhao Y; Zhu FC; Hu YM; Meng FY; Li JX; Luo L; Yang JY; Liu P; Yu J
Expert Rev Vaccines; 2017 Nov; 16(11):1155-1169. PubMed ID: 28870140
[TBL] [Abstract][Full Text] [Related]
18. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.
Haralambieva IH; Painter SD; Kennedy RB; Ovsyannikova IG; Lambert ND; Goergen KM; Oberg AL; Poland GA
PLoS One; 2015; 10(3):e0122282. PubMed ID: 25816015
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Older Adults' Immune Responses to Seasonal Influenza Vaccination.
Voigt EA; Ovsyannikova IG; Kennedy RB; Grill DE; Goergen KM; Schaid DJ; Poland GA
Front Immunol; 2019; 10():180. PubMed ID: 30873150
[No Abstract] [Full Text] [Related]
20. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.
Ray R; Dos Santos G; Buck PO; Claeys C; Matias G; Innis BL; Bekkat-Berkani R
Hum Vaccin Immunother; 2017 Jul; 13(7):1640-1652. PubMed ID: 28532276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
